Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs
Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets
You may also be interested in...
Report from Licensing Executives Society meeting: Survey shows many already have taken action oncomparative effectiveness.
Investors push the stock down on its first day, but the Seattle biotech now has cash to help get its late-stage pain compound to market.
BIO executive VP John Taylor returns to the agency as special counselor while FDA also fills another key liaison slot.